Dr. Louis “Skip” Vignati, Senior Medical Consultant, is a board-certified endocrinologist with broad clinical and drug discovery experience spanning 40 years. Dr. Vignati served as Vice President, Medical Affairs at Calibrium, a biotech company developing novel biotherapeutics for the treatment of diabetes, from June 2014 until Calibrium was acquired by Novo Nordisk in December 2015. Previously, he was Vice President, Medical at Marcadia Biotech, a pioneer in peptide multi-agonists of incretin receptors, from September 2006 to April 2011. Marcadia was acquired by Roche in December 2010.

He received an undergraduate degree from the University of Pennsylvania, a graduate degree in organic chemistry from American University and a medical degree from Thomas Jefferson University. He completed his house staff training at the University of Vermont and Endocrine Fellowship at the Peter Bent Brigham Hospital and the Elliot P. Joslin Research Laboratory in Boston, Massachusetts. He served as an officer in the USPHS in the Toxicology Branch of the National Institute of Health for Occupational Safety and Health.

Following his fellowship, Dr. Vignati was senior physician at the Joslin Diabetes Center in Boston, Massachusetts. In 1990 he joined Eli Lilly and Company and served as the Medical Director for development of early phase endocrine compounds. At Lilly he participated in the global development of new therapies for the treatment of diabetes and its complications and obesity including Humalog®, Recombinant Glucagon®, and Forteo® among others. Dr. Vignati has been a principal investigator for numerous clinical trials and co-investigator for the DCCT (Diabetes Control and Complications Trial).